Literature DB >> 16418888

Systemic chemotherapy should be the primary treatment of synchronous colorectal metastases in the asymptomatic patient [corrected].

Nicholas J Petrelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16418888     DOI： 10.1245/ASO.2006.05.059

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Stage IV colorectal cancers: an analysis of factors predicting outcome and survival in 728 cases.

Authors:  Min-Hoe Chew; Jin-Yao Teo; Tousif Kabir; Poh-Koon Koh; Kong-Weng Eu; Choong-Leong Tang
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

2.  Timing of Perioperative Chemotherapy Does Not Influence Long-Term Outcome of Patients Undergoing Combined Laparoscopic Colorectal and Liver Resection in Selected Upfront Resectable Synchronous Liver Metastases.

Authors:  Francesca Ratti; David Fuks; Federica Cipriani; Brice Gayet; Luca Aldrighetti
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

3.  Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective.

Authors:  George A Poultsides; Phillip B Paty
Journal:  Ther Adv Med Oncol       Date:  2011-01       Impact factor: 8.168

4.  Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone.

Authors:  A P Stillwell; P G Buettner; Y H Ho
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

5.  Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.

Authors:  George A Poultsides; Elliot L Servais; Leonard B Saltz; Sujata Patil; Nancy E Kemeny; Jose G Guillem; Martin Weiser; Larissa K F Temple; W Douglas Wong; Phillip B Paty
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

6.  Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.

Authors:  Laurence E McCahill; Greg Yothers; Saima Sharif; Nicholas J Petrelli; Lily Lau Lai; Naftali Bechar; Jeffrey K Giguere; Shaker R Dakhil; Louis Fehrenbacher; Samia H Lopa; Lawrence D Wagman; Michael J O'Connell; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

7.  Colorectal liver metastases.

Authors:  Ashraf J Haddad; Murad Bani Hani; Timothy M Pawlik; Steven C Cunningham
Journal:  Int J Surg Oncol       Date:  2011-06-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.